Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -22K | -18K | -6K | 0 |
| Operating Income | -57M | -2M | -2M | -2M | -2M |
| EBITDA | -58M | -1M | -2M | -2M | -2M |
| Net Income | -59M | -2M | -3M | -3M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.38
+0.73% today
1Y Change
-98.62%
Window
Jun 23, 2025 → Jun 9, 2026
Coverage: 242 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Propanc Biopharma, Inc. (PPCB) is a Healthcare stock with listed on NASDAQ. The stock last traded around $1.38 and down 98.6% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +99.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +99.0%, free cash flow +56.7% with operating margin -217705.1% and ROIC -538.0%. Valuation already assumes a fairly strong business story at price/sales 52.4. Stock Foundry combines PPCB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PPCB
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PPCB Max Drawdown
-99.47%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PPCB and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$2.0M
+23.8% YoY
Free Cash Flow
-$1.1M
+20.3% YoY
Revenue Growth
+0.0%
EPS Growth
+99.0%
Gross Margin
0.4%
Net Margin
-220932.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -22K | -18K | -6K | 0 |
| Operating Income | -57M | -2M | -2M | -2M | -2M |
| EBITDA | -58M | -1M | -2M | -2M | -2M |
| Net Income | -59M | -2M | -3M | -3M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 12K | 21K | 10K | 4K | 2K |
| Total Assets | 20M | 72K | 60K | 82K | 13K |
| Total Liabilities | 6M | 4M | 3M | 3M | 3M |
| Shareholder Equity | 14M | -4M | -3M | -3M | -3M |
| Total Debt | 2M | 948K | 546K | 1M | 680K |
| Net Debt | 2M | 927K | 536K | 1M | 678K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
+20.3% YoY
Capital Expenditures
4
+0.0% YoY
Free Cash Flow
1M
+20.3% YoY
Key ratios
Gross Margin
0.4%
Operating Margin
-217705.1%
Net Margin
-220932.3%
ROE
-465.2%
Debt / Equity
0.16x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.